Bortezomib in the treatment of refractory kidney graft rejection
Background. Bortezomib, a 26S proteasome inhibitor, is a novel treatment for refractory acute rejection. The main mechanism proposed for its action is the induction of apoptosis of mature plasma cells leading to an interruption of donor-specific antibody production, but other properties may also be...
| Autor principal: | |
|---|---|
| Outros Autores: | , , , , , , |
| Formato: | other |
| Idioma: | eng |
| Publicado em: |
2012
|
| Assuntos: | |
| Texto completo: | http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692012000400009 |
| País: | Portugal |
| Oai: | oai:scielo:S0872-01692012000400009 |